Sonnet BioTherapeutics, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)

9 Months Ended

Sep. 30, 2016

The Company also has issued warrants to investors in connection with financing transactions in prior periods. A summary of the warrants outstanding and related activity is presented below:

	Number of Warrants		Weighted Average Exercise Price		Weighted Average Remaining Life
Outstanding January 1, 2016		9,506,304	$	4.93		1.9
Granted		-		-
Exercised		-		-
Forfeited		-		-
Outstanding September 30, 2016		9,506,304	$	4.93		1.9

Exercisable September 30, 2016		9,506,304	$	4.93		1.9

Schedule of Warrants Outstanding

Exercise Price	Outstanding Number of Warrants		Weighted Average Remaining Life in Years		Exerciseable Number of Warrants

>$4.00		7,439,631		1.8		7,439,631
$3.00-$3.99		799,901		1.8		799,901
$2.00-$2.99		954,272		2.8		954,272
$1.00-$1.99		312,500		3.2		312,500
		9,506,304				9,506,304

- Definition

Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.

+ References + Details